Effective Administration and Management of Anti-GD2 Monoclonal Antibodies for Pediatric Neuroblastoma

Target Audience
The educational design of this activity addresses the needs of pediatric oncology nurses, advanced practice providers (including nurse practitioners and physician assistants), pediatric oncologists, social workers, and other members of the team caring for children with pediatric neuroblastoma.

Statement of Need/Program Overview
Next-generation anti-GD2 therapies have expanded the treatment landscape for relapsed/refractory high-risk pediatric neuroblastoma. With few treatment options in this setting, anti-GD2 agents hold the promise of reducing the burden of care on patients and their families, including time spent in the hospital and financial, professional, and personal concerns.

To help achieve these goals, this activity will provide clinicians with critical updates on the scientific evidence related to these therapies. A multidisciplinary panel of experts in pediatric neuroblastoma and anti-GD2 therapy will review the nuances of treatment administration and delivery, along with the management of adverse events. Return to your practice with supportive-care protocols designed to facilitate safe and effective care for your patients with pediatric neuroblastoma, and to improve quality of life for these patients and their families.

Educational Objectives
After completing this activity, the participant should be better able to:

Review the historical evolution of anti-GD2 therapy and the rationale for novel therapies
Differentiate administration protocols for currently available anti-GD2 therapies
Assess the demands on the inpatient vs the outpatient treatment teams
Evaluate supportive-care strategies to manage the challenges of administration and treatment-related adverse effects of anti-GD2 therapy for pediatric neuroblastoma